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Abstract
The imaging manifestations of hepatic lymphoma, both in
its primary and secondary form, are extremely variable
and overlap with a number of other more common hepatic
diseases. However, in the appropriate clinical context,
combining the imaging and laboratory features can aid
in making the correct diagnosis. Since the management
and prognosis of lymphomas are significantly different
from other malignancies, early diagnosis and prompt
commencement of therapy is of paramount importance.
The various morphological appearances of hepatic
lymphoma on imaging have been described here along
with their possible differentials.
Teaching points
• Primary hepatic lymphoma is extremely rare.
• Secondary liver involvement occurs in 50 % of patients with
non-Hodgkin lymphoma.
• The imaging manifestations of hepatic lymphoma are largely
non-specific.
• Some imaging features may be helpful in the appropriate
clinical setting.
• Management and prognosis of lymphoma is significantly
different from other malignancies.
Keywords Hepatic lymphoma . Hepatitis-C . Periportal .
Rim-enhancement . Scar
Introduction
Secondary involvement of the liver can occur in up to 50 % of
patients with non-Hodgkin lymphoma and in around 20 % of
patients with Hodgkin disease [1, 2]. However, primary he-
patic lymphoma (PHL) is rare, representing <1 % of all non-
Hodgkin’s lymphoma [3, 4]. The past two decades have seen
an increase in the number of reported cases of PHL, especially
in the setting of immunosuppression [5–15]. Although the
imaging manifestations of hepatic lymphomas are largely
non-specific, there are some features that may serve as a useful
diagnostic clue in the apppropriate clinical setting. Since
multiagent chemotherapy is the mainstay of treatment in sec-
ondary hepatic lymphoma (SHL) with surgery being reserved
for cases of PHL with resectable disease, early and accurate
diagnosis can alter the therapeutic protocol and obviate the
need for unnecessary radical surgery. In this article, we at-
tempt to classify hepatic lymphomas based on the different
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discuss the various other more common hepatic lesions that
need to be differentiated from lymphoma.
Primary hepatic lymphoma
PHL is defined as lymphoma that is confined to the liver and
perihepatic lymph nodes, without evidence of involvement of
other visceral organs, distant lymph nodes or bone marrow for
at least 6-months after the onset of hepatic disease [16]. PHL
should be differentiated from lymphoma that secondarily af-
fects the liver because the management and prognoses differ
significantly. Although first described way back in 1965 by
Ata and Kamal [17], only 100 odd cases of PHL have since
been reported in English-language medical literature [8, 18].
This is because host factors can make the liver a poor envi-
ronment for the development of malignant lymphoma [8].
PHL is usually diagnosed in the 4th-5th decade and shows
a male predominance [14]. It is commonly associated with
viral hepatitis B and C, Epstein-Barr virus, and human immu-
nodeficiency virus [14]. Hepatitis-C viral infection is particu-
larly common, being found in 20–60 % of patients with PHL
[19, 20]. Clinical symptoms including right upper abdominal
pain, weight loss, and fever can be seen in up to 50% of cases.
The majority of the cases of PHL are of B-cell lineage, and
diffuse large B-cell lymphoma is the most commonly detected
histological subtype [14].
Secondary hepatic lymphoma
Secondary hepatic involvement by lymphoma is relatively
common and indicates advanced disease. Patients usually
present with systemic symptoms of fever, night sweats, and
weight loss. Hepatosplenomegaly and generalized lymphade-
nopathy can be commonly found on systemic examination
[21]. Mild elevation of serum transaminases and moderate
elevation of alkaline phosphatase (ALP) can occur due to
tumour infiltration or extrahepatic bile duct obstruction [21].
Differences between primary and secondary hepatic lympho-
ma have been summarized in Table 1.
Other forms of lymphoma
Hepatosplenic T-cell lymphoma is a rare and poorly recog-
nized entity characterized by neoplastic proliferation of T-
cells in hepatic sinusoids and splenic red pulp without lymph-
adenopathy and bone marrow involvement [22–26]. More
recently, hepatic involvement by the intravascular variety of
lymphoma has also been described caused by neoplastic pro-
liferation in the lumen of small- to medium-sized hepatic ves-
sels [27, 28]. However, due to paucity of literature on these
forms of lymphoma, no specific imaging features have been
recognized. The reported cases of hepatosplenic lymphoma
usually presented with features of hepato-splenomegaly or
cirrhosis without evidence of any focal lesions [24–26], while
Table 1 Clinical and radiological manifestations of primary vs. secondary hepatic lymphoma
Primary hepatic lymphoma Secondary hepatic lymphoma
Clinical Definition Lymphoma confined to the liver and
perihepatic nodal sites (without distant
involvement) at time of presentation
Lymphoma that secondarily
affects the liver
Incidence 1 % of non-Hodgkin lymphoma 50 % of non-Hodgkin lymphoma
20 % Hodgkin lymphoma
Associations Epstein-Barr virus, hepatitis B and C
infection, HIV infection and cirrhosis
-
Presenting complaints Right upper quadrant pain, jaundice (10-
20 %)
Systemic symptoms (B symptoms)
such as fever, night sweats,
weight loss




Absent (for at least for 6 months after
first presentation)
Present
Radiological Lesion distribution Solitary discrete lesion (60 %), multiple
lesions (35-40 %)
Multifocal lesions or diffuse
infiltration (90 %)
Miliary shadows (10 %)
Dominant mass(es) Typically present Usually absent
Morphology Heterogeneous Homogeneous
Enhancement Heterogeneous Heterogeneous
Splenic lesions Absent Present (30-40 %)
Supra-and/or infra-diaphragmatic lymphadenopathy Absent Present
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the only report on the imaging manifestations of hepatic intra-
vascular lymphoma described non-specific focal liver lesions
and areas of uneven perfusion [27].
Imaging features
Lymphomatous involvement of liver can manifest on imaging
as solitary or multiple nodular lesions, diffuse infiltration, or
as a periportal soft tissue mass [15, 28, 29]. A combination of
infiltrating and nodular patterns has also been described.
1. Nodular (mass-forming) pattern
(a) Solitary discrete lesion
This is the most common presentation of PHL on
imaging, seen in approximately 60 % of cases
[12–14]. SHL, on the other hand, manifests in this
manner in only about 10 % of cases. On ultrasound
(US), the lesion is usually well defined and appears
markedly hypoechoic or anechoic, occasionally
mimicking a cyst [10, 29] (Fig. 1). This is because
lymphoma is a homogeneous tumour and generates
very few internal reflections. However, absence of
posterior acoustic enhancement can be a useful
pointer towards the solid nature of the lymphoma-
tous lesion [29]. Perihepatic regional lymph nodal
involvement is commonly seen. Instances of hepatic
lymphoma being confused with an abscess on ultra-
sound (US) have also been reported [30–32]. The
hypoechoic appearance of lymphoma along with
the presence of fever and other systemic symptoms
in these patients may make it extremely difficult to
distinguish lymphoma from an abscess (Fig. 2). Pres-
ence of mobile internal echoes, septations, and het-
erogeneity favours the diagnosis of abscess. In addi-
tion, reactive right pleural effusion, ascites, and bow-
el abnormalities (caecal wall thickening in cases of
amoebic infection) can be found in patients with he-
patic abscess (Table 2).
The lesion is usually homogeneously hypodense
on non-contrast-enhanced computed tomographic
(CT) scan and has soft tissue attenuation. Areas of
necrosis and haemorrhage may occasionally be seen.
However, calcification is rare in the absence of treat-
ment [29].
Upon administration of intravenous contrast
agent, two different types of enhancement patterns
have been recognized in lymphomatous nodules.
These enhancement characteristics also apply to the
multinodular pattern of lymphomatous liver infiltra-
tion described later:
& Majority of the lesions demonstrate minimal to no en-
hancement on all the phases [12, 29]. Enhancement, when
present, is characteristically less than the surrounding he-
patic parenchyma (Fig. 3). However, multiple vascular
channels can often be seen coursing through the lesion.
This has been referred to as the Bvessel penetration sign^
(Fig. 4). In addition to this, the absence of any significant
surrounding oedema and pylephlebitis can be used to dif-
ferentiate lymphoma from hepatic abscess. Since PHL is
commonly associated with Hepatitis-C and B viral infec-
tions, one may come across lymphomatous hepatic lesion
on a background of cirrhotic liver (Fig. 4). In these in-
stances, it may be difficult to differentiate PHL from he-
patocellular carcinoma (HCC). However, in typical cases,
absence of significant arterial phase enhancement, vessel
penetration sign, and absence of vascular thrombosis are
useful clues to diagnose lymphoma (Table 2). In addition,
Fig. 1 Incidentally detected PHL in a 76-year-old man with acute pan-
creatitis. a Gray-scale US images demonstrating a lobulated anechoic
lesion (partly marked by calipers) in the gastrohepatic ligament abutting
the liver. This was reported as suspicious for pancreatic pseudocysts in
view of the clinical history. b Axial CECT image of the same patient
showing a homogeneous, partially exophytic, hypoenhancing mass
(asterisk) replacing the caudate lobe of the liver and involving the adjoin-
ing hepatic parenchyma. Biopsy from the liver lesion revealed findings
consistent with diffuse large B-cell lymphoma. Sequel of acute pancrea-
titis can be seen as ill-defined soft tissue stranding along the greater
curvature of the stomach (arrow)
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laboratory investigations like tumour markers can also be
used to support the imaging diagnosis.
Occasionally, a central Bscar^ can be seen in this type
of hepatic lymphoma, mimicking focal nodular hyperpla-
sia [33] (Fig. 5). However, poor enhancement of the lesion
on all the contrast-enhanced phases allows one to confi-
dently differentiate between the two entities.
& Theotherpatternisthatofenhancementoftherimofthelesion
withacentralnon-enhancingareagivinga target-likeappear-
ance to the lesion [29, 34].Due to thewell-defined, lobulated
outline of these lesions and the predominantly peripheral en-
hancement,whichpersists evenon theequilibriumphase im-
ages, theycanbemisdiagnosedas intrahepatic cholangiocar-
cinoma on imaging (Fig. 6). But, unlike a cholangiocarcino-
ma, capsular retraction andmass effect in the form of biliary
dilatation and vascular displacement is typically absent in
hepatic lymphoma. Also, CA-19.9 levels are often signifi-
cantly increased in cholangiocarcinoma.
Fig. 2 PHL in a 42-year-old man with right upper abdominal pain. Gray-
scale US image showing a partially exophytic hypoechoic lesion
(asterisk) in the right lobe of liver suspicious for abscess. The patient
underwent diagnostic aspiration followed by biopsy from the lesion,
which revealed findings consistent with diffuse large B-cell lymphoma
Table 2 Differentials of various morphological types of hepatic lymphoma
Morphological Type Differentials Distinguishing feature(s)
Solitary discrete lesion Cyst - Posterior acoustic enhancement on US
Abscess - Mobile internal echoes, septations and heterogeneity on US
- Reactive right pleural effusion, ascites and caecal wall thickening
- Presence of surrounding edema and pylephlebitis
- Absence of vessel penetration sign
Hepatocellular carcinoma (HCC) - Arterial phase enhancement
- Venous invasion/thrombosis
- Raised alpha-fetoprotein levels
Focal nodular hyperplasia - Homogeneous enhancement
Intrahepatic cholangiocarcinoma - Capsular retraction
- Mass effect in the form of biliary dilatation and vascular displacement
- Increased CA-19.9 levels
Multifocal lesions Tuberculosis - Necrotic rim-enhancing lymph nodes




Fungal microabscesses - Perilesional edema
- History of immunosuppression
- High-grade fever with increased white blood cell count
Septic emboli - Known source of infection
- Clinical features of sepsis
Metastases - Known primary malignancy
Diffuse infiltration Infiltrative HCC - Venous invasion/thrombosis
- Markedly raised alpha-fetoprotein levels
- Often non-avid on FDG PET-CT
Acute viral hepatitis - Echogenic periportal cuffing on US
- Normal or mildly elevated LDH levels
- Significant elevation of transaminases
Periportal mass Periportal edema - Echogenic on US
- History of trauma, surgery
Biliary dilatation - Anechoic tubular structures on US
- Absence of complete encasement of portal venous radicals
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Onmagnetic resonance (MR) imaging, the lesion tends to
be homogeneously hypo to isointense on T1-weighted im-
ages and hyperintense on T2-weighted images [29, 35]. Sig-
nal intensity on T2-weighted images may be heterogeneous
duetofociofhaemorrhageandnecrosis[12].T2-hypointense
tumourswithperipheral rimof hyperintensity havealsobeen
reported. The increased signal around the lesion has been
attributed to the inflammatory response elicited by the lym-
phomatous lesion and resultant surrounding oedema [12].
Similarly, target-like lesions showing a T2-hyperintense rim
with a slightly more hyperintense core can also be seen
(Fig.6).EnhancementpatternsonMRIaresimilartothatseen
on CT. However, when hepatobiliary specific MRI contrast
mediaareused, retentionofcontrastbythecentreof thelesion
can be seen on the delayed hepatobiliary phase (Fig. 6).
Thehighlycellularnatureoflymphomatypicallyresults in
restricted diffusion and whole-body diffusion-weighted im-
aginghasbeensuggestedtobeassensitiveasFDG-PET/CTin
staging of lymphoma [36]. Occasionally a rim of diffusion
restrictionmayalsobeseen(Fig.6).Moreover,quantification
of diffusion effects of the tumour usingmean apparent diffu-
sioncoefficient(ADC)valuesalsohelpsincharacterizationof
these lesions. Using b values of 100, 500, and 750 s/mm2,
Badawy et al. [37] demonstrated that hepatic lymphomas
showedmeanADCvaluesof1.37,1.20and1.18, respective-
ly, whichwere significantly lower than that for benign cystic
hepatic lesionsandbenigntumours likehemangioma,adeno-
ma, and FNH,while being similar tomalignant tumours like
HCC. They concluded that using different b values can not
only increase sensitivity for detection of additional liver le-
sions but also offers the possibility to characterize focal liver
lesions into benign and malignant without the need for con-
trast agent administration by usingADCmeasurements.
FDG-PET/CT is the imagingmodality of choice for stag-
ing and response assessment of FDG-avid lymphomas and
obviates the need for pretreatment bone marrow biopsy in
patients with Hodgkin lymphoma and most cases of diffuse
large B-cell lymphoma [38]. On FDG-PET/CT, the lesion
typically demonstrates avid hypermetabolism (Fig. 7). The
value of FDG-PET/ CT in addition to CT lies in the high
lesion-to-background contrast and quantification of glucose
metabolism (usingmeasurement of standardized uptake val-
ue). Standardized uptake value may also be valuable as a
biomarker in assessing the tumour grade, for guiding biopsy,
and for determination of response to therapy in patients with
lymphoma. Disadvantages of FDG-PET/CT, however, are
exposure of the patient to ionizing radiation and relatively
highcost.Anumberofstudieshaverecentlycomparedwhole
body DWI with FDG-PET/CT in staging of lymphoma at
initial presentationandhave foundmoderate togood interob-
server agreement [36]. Since MRI does not entail ionizing
radiation, allows cross-sectional imaging of the entire body,
providesahighersoft-tissuecontrast,andoffersawidevariety
of anatomical and functional sequences, itmay be used as an
alternative to FDG-PET/CT in this regard [36]. However,
there are still no recommendations on the routine use of
MRI in this regard.
(b) Multifocal lesions (with or without a dominant mass)
Multiple discrete hepatic lesions of varying sizes
have been reported at presentation in approximately
35- 40 % of cases of PHL [10, 12], although one of
the lesions is typically dominant [29]. In contrast,
multifocal lesions or diffuse infiltration is the most
common pattern of liver involvement in SHL, seen
in up to 90 % of cases. Dominant masses are usually
absent in SHL. Also, untreated nodules in SHL, even
when large, are usually homogeneous (Fig. 8), while
the dominant masses in PHL are typically heteroge-
neous. Concomitant splenic lesions can be seen in
30-40 % of patients with SHL, which, along with
widespread infra- or supradiaphragmatic lymphade-
nopathy and bone marrow infiltration facilitate
Fig. 3 SHL in a 38-year-oldmanwith fever and significant weight loss. a
Gray scale US image showing a large lobulated hypoechoic lesion
(marked by calipers) in the right lobe of liver. b Axial CECT image
demonstrating a subtle well-defined hypoenhancing lesion (asterisk) in
liver with perihepatic lymph nodes (arrow), splenomegaly, and altered
enhancement of the splenic parenchyma (arrowheads)
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correct diagnosis [29]. The nodules are markedly
hypoechoic on US. They may also have a target ap-
pearance, with central echogenic and peripheral
hypoechoic components (Fig. 9). As mentioned pre-
viously, the enhancement patterns of the individual
lesions in multinodular lymphoma are essentially
similar to those described above for the solitary
mass-forming variety of lymphoma. Thus, the nod-
ules are typically diffusely hypoenhancing compared
to the surrounding hepatic parenchyma. Patchy en-
hancement or rim-enhancement of the nodules can
be seen in up to 15 % of cases (Figs. 10 and 11).
OnMR imaging, the nodules are usually hypo- or
isointense on T1-weighted images and hyperintense
on T2-weighted images, although T2-hypointense
nodules mimicking hepatic sarcoidosis have been
reported [12].
The list of differentials for the multifocal pattern
of presentation of hepatic lymphoma is long and in-
cludes disseminated granulomatous infections (tu-
berculosis and sarcoidosis), fungal microabscesses,
septic emboli, and metastases. Of these, hepatic in-
volvement caused by granulomatous diseases can be
particularly challenging to differentiate from lym-
phoma, since they can also result in hypoenhancing
hepato-splenic lesions with splenomegaly and exten-
sive lymphadenopathy. In addition, systemic symp-
toms of fever and weight loss are also commonly
present, further confounding the issue. Presence of
necrotic rim-enhancing lymph nodes in tuberculosis
and T2-hypointense nodules in sarcoidosis along
with the characteristic pattern of lung involvement
in these granulomatous infections and clinical inputs
are often helpful in making a correct diagnosis [39],
although such differentiation is not always achiev-
able in practice.
Fig. 4 Primary hepatic non-
Hodgkin lymphoma in a 55-year-
old man with jaundice. a Gray-
scale US image showing a large,
well-defined, markedly
hypoechoic lesion in the right
lobe of liver (marked by calipers).
CECT images (b-d)
demonstrating a hypoenhancing
lesion (asterisks) with arterial
channels coursing through it
(arrows in b and c). Changes of
liver cirrhosis and ascites can also
be seen with biliary dilatation
(arrow in d). MR images reveal a
homogeneous, mildly T2-
hyperintense, diffusion restricting
lesion (asterisk in e and f)
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In the case of fungal microabscesses, patients
commonly provide a his tory of immune-
suppression and present with high-grade fever and
a raised white blood cell count. Perilesional oedema
can be demonstrated in fungal microabscesses, al-
though this may not be appreciable in smaller le-
sions. Patients with septic emboli usually have a
known source of infection. Similarly, metastatic dis-
ease should be considered when there is evidence of
a known primary in the patient.
2. Diffuse infiltration
Infiltration of tumour cells into the portal tracts as well
as sinusoids is one of the most common patterns of hepat-
ic involvement in cases of SHL. It is rare in PHL, but
when present, it portends a poor prognosis [13]. There
are no specific imaging features, and the only sign of
hepatic involvement is diffuse enlargement of liver
(Fig. 12). However, relying purely on physical examina-
tion or the measurement of the cranio-caudal span of liver
on CT to detect enlargement can often produce fallacious
results, especially on initial evaluation. This is because
liver size is affected by body habitus, race, and a number
of unrelated systemic diseases. Moreover, absence of uni-
versally accepted guidelines for the measurement of liver
span on imaging affects interobserver agreement and re-
producibility of these measurements. In these cases, as-
sessment of liver volume using commercially avail-
able software (Myrian® XP Liver) provides an ac-
curate and objective measure of liver enlargement,
which can also be effectively reproduced on
follow-up scans. FDG-PET/CT has also been shown
to be helpful in these cases by demonstrating diffuse
FDG uptake in the enlarged liver and spleen with
systemic FDG-avid lymphadenopathy [40].
Fig. 5 Diffuse large B-cell
lymphoma with secondary liver
involvement in a 57-year-old
man. (a) Axial T2-weighted MR
image demonstrating a well-
defined, lobulated, mildly
hyperintense lesion (arrow) with a
more hyperintense central Bscar.^
It shows peripheral diffusion
restriction (arrow in b). The lesion
is hypointense on T1-weighted
image (arrow in c). On contrast-
enhanced scan the lesion shows
mild progressive enhancement in
the arterial and venous phase
images (arrows in d and e), which
is less than the surrounding liver
parenchyma while the scar
remains predominantly non-
enhancing. On the 1-hr delayed
hepatobiliary phase, the lesion
remains hypointense to the
surrounding liver parenchyma
while there is retention of contrast
within the scar
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In cases of segmental hepatic infiltration, subtle
T2-hyperintensity with diffusion restriction can oc-
casionally be seen. Infiltrative HCC may be difficult
to distinguish from this pattern of lymphomatous
hepatic involvement, since both these entities can
occur in cirrhotic livers and have similar imaging
characteristics [41]. However, tumoral infiltration
and attendant thrombosis of adjoining portal venous
radicals is commonly seen in cases of infiltrative
HCC, and the levels of alpha fetoprotein are usually
markedly raised. Lymphoma, on the other hand, of-
ten presents with concomitant splenomegaly, lymph-
adenopathy below the level of the renal veins, and
causes vascular encasement without thrombosis. Al-
so, in general, hepatic lymphomas are avidly hyper-
metabolic at PET, while most HCCs are not.
Not infrequently, patients with diffuse infiltrating
lymphoma can present with fulminant hepatic failure
due to extensive infiltration of sinusoids and hepatic
vasculature by malignant cells resulting in diffuse
hepatic necrosis [42]. On imaging, a diffusely
oedematous gall bladder wall can be seen along
with hepatosplenomegaly, ascites, and perihepatic
lymphadenopathy mimicking acute viral hepatitis
(AVH) [43]. Clinical deterioration in these patients
often occurs rapidly and liver biopsy is usually re-
quired to make an accurate diagnosis although, in
rare instances, even a biopsy might be inconclusive
[44].
A combination of infiltrating and nodular pattern
of hepatic involvement can also be seen on imaging
resulting in diffuse hepatic enlargement with multi-
ple subtle hypoenhancing nodules scattered in the
liver parenchyma (Fig. 13).
3. Periportal mass
Periportal spread of lymphoma can be explained by the
fact that lymphatic vessels along the portal vein and bile
ducts are responsible for 80 % of hepatic lymph drainage
Fig. 6 Rim-enhancing masses in
a 65-year-old woman with PHL.
Axial T2-weighted fat-saturated
MR image showing a well-
defined lobulated hyperintense
lesion (solid arrow in a) with
peripheral diffusion restriction
(b). Multiple other similar but
smaller nodules (interrupted
arrows) are also seen. Post
contrast administration, rim-
enhancement of the dominant
lesion is seen on the arterial phase
image (c) with partial progressive
centripetal fill-in of contrast on
the subsequent portal venous (d)
and equilibrium phase images (e).
On the 1-hr delayed hepatobiliary
phase, the central portion of the
tumor shows accumulation of
contrast. The other nodules also
demonstrate similar enhancement
pattern
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[45]. This variant is being increasingly recognized and
manifests in the form of periportal soft-tissue cuffing or
ill-defined mass [46–48]. Both primary and secondary
forms of hepatic lymphoma can present in this manner.
When the involvement is limited to periportal soft
tissue cuffing, this variety of hepatic lymphoma should
be differentiated from the other causes of Bperiportal
halo^ like biliary dilatation, lymphedema (secondary to
transplantation or portal lymphadenopathy), trauma, car-
diac failure, and AVH. Out of these, AVH can be par-
ticularly difficult to differentiate from lymphoma on CT
and MRI because in both these conditions, patients pres-
ent with hepatosplenomegaly and periportal cuffing in
the setting of deranged liver functions. However, US is
Fig. 7 Axial contrast-enhanced CT (a) and corresponding FDG-PET (b)
images of the same patient as in Fig. 6 showing avid FDG uptake within
the predominantly hypoenhancing hepatic lesions (Image courtesy: Dr.
Ishita Sen, Dept. of NuclearMedicine, Fortis Memorial Research Institute,
Gurgaon)
Fig. 8 CT findings in SHL from two different patients. Axial CECT
images demonstrating multiple homogeneous hypoenhancing hepatic
lesions. Splenic lesions and perihepatic lymph nodes can also be seen in
the image b
Fig. 9 Secondary anaplastic large cell lymphoma of liver in a 48-year-
old man. Gray-scale US image demonstrating a focal nodular lesion in
liver (solid arrow), which shows a central echogenic component and a
peripheral ill-defined hypoechoic ring (target-sign). Multiple other
hypoechoic lesions can also be seen (interrupted arrows) in liver. This
appearance cannot be distinguished from metastases on imaging, and
tissue diagnosis is mandatory in the absence of any known primary
malignancy
Fig. 10 PHLmanifesting as multifocal lesions in a 67-year-oldmale with
fatigue and weight loss. Axial CECT image showing a hypoenhancing
dominant lesion in the right lobe of liver (arrow) with vessel penetration
sign (asterisk). Few other similar but smaller lesions are noted in the left
lobe (arrowheads)
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helpful in such cases because periportal cuffing in lym-
phoma is usually hypoechoic while in AVH, it is
echogenic (Fig. 14). Additionally, in AVH, direct and
indirect bilirubin levels are usually elevated in roughly
equal proportions and ALP and lactate dehydrogenase
(LDH) levels are normal or only mildly elevated. In
contrast, moderate elevation of ALP and LDH can occur
in lymphoma due to tumour infiltration or extrahepatic
b i l e duc t obs t ruc t ion wi th resu l t an t d i r ec t
Fig. 11 SHL in a 56-year-old man with fever and significant weight loss.
a Multiple well-defined variable sized diffusion restricting nodules are
seen involving both liver and spleen. b On post administrations of intra-
venous contrast, the nodules demonstrate rim-enhancement. This appear-
ance can be difficult to differentiate from abscesses and disseminated
granulomatous infections. Histopathological examination revealed this
to be diffuse large B-cell lymphoma with bone marrow involvement
Fig. 12 Infiltrating SHL in an 18-year-old female with abdominal pain
and distension. Axial CECT image demonstrating diffuse enlargement of
liver and spleen without any evidence of focal hepatosplenic lesions
Fig. 13 Mixed infiltrating and nodular variety of SHL in a 57-year-old
man. Axial CECT image showing ill-defined hypoenhancing lesions in
the left lobe of liver (arrows) on a background of hepatomegaly. Liver
biopsy revealed lymphomatous infiltration of hepatic sinusoids
Fig. 14 Non-Hodgkin lymphoma in a 34-year-old female with fulminant
hepatic failure. Gray-scale US images demonstrating diffuse linear as
well as nodular hypoechoic periportal cuffing (arrowheads and arrow,
respectively). The patient had a rapidly downhill clinical course and
succumbed to her illness within a week of admission. Post-mortem liver
biopsy revealed findings consistent with diffuse large B-cell lymphoma
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hyperbilirubinemia. Also, in lymphoma, only a mild in-
crease in serum transaminases is seen while AVH causes
significant elevation in serum transaminase levels, often
reaching up to 100 times their normal ranges. Viral
markers can also used to differentiate between the two,
although the coexistence of Hepatitis-B and C infection
in patients with lymphoma limits its diagnostic utility.
Bile duct dilatation can be differentiated from lympho-
ma by the complete encasement of the portal vessels by
the tumour and its hypoechoic appearance as opposed to
the anechoic biliary radicals. Other causes of
periportal halo can usually be diagnosed on the ba-
sis of clinical history.
More commonly, however, a large seemingly in-
filtrating juxta-hilar mass is seen tracking along the
biliary radicals and portal tracts. On US, the mass is
usually hypoechoic. However, areas of heterogeneity
as well as completely echogenic lesions have also
been reported [49]. On CT, these masses are homo-
geneously hypodense and show poor enhancement
(Fig. 15). Also, as previously described, they encase
the portal vessels but do not occlude them, connot-
ing their pliable nature and soft texture. Owing to its
better soft tissue contrast, MR imaging can delineate
the entire extent of these tumours, particularly when
combined with diffusion weighted imaging. The se-
verity of biliary dilatation can also be assessed si-
multaneously (Fig. 16).
Fig. 15 SHL in a 60-year-old man with jaundice. Axial CECT images
demonstrating an ill-defined hypoenhancing periportal soft-tissue mass
(solid black arrows in a and b) causing mild dilatation of the intrahepatic
biliary radicals (white arrows). Portal vein and hepatic artery (asterisks in
a and b, respectively) are seen coursing through the lesion without being
attenuated or thrombosed. Bilateral kidneys are also involved (interrupted
arrows)
Fig. 16 MRI findings in
periportal infiltrating variety of
hepatic lymphoma in a 60-year-
old man. Axial (a and b) and
coronal (d) T2-weighted and
diffusion weighted (c) MR
images demonstrating a mildly
hyperintense ill-defined juxta-
hilar diffusion restricting mass
(arrowheads) completely
encasing the common bile duct
(solid arrow in d) and vessels at
porta with resultant upstream
biliary dilatation (interrupted
arrows). A vertebral lesion is also
seen (solid arrow in b and c)
along with perihepatic and splenic
hilar lymph nodes (asterisks in c)
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Staging and follow-up
Currently, prognostic indices are mostly used to risk-stratify
patients and decide therapy, but most of these indices include
stage as a factor, so imaging-determined stage remains rele-
vant. A modification of the Ann-Arbor classification has been
retained for this purpose in the Lugano criteria (Table 3) [38].
Treatment is practically based on limited (stages I and II,
nonbulky) or advanced (stages III or IV) disease, with stage
II bulky disease considered limited or advanced as determined
by histology and a number of prognostic factors. The desig-
nation E is used for limited extranodal disease in the absence
of nodal involvement (stage IE) or in patients with stage II
disease and direct extension to a non-nodal site. E is not rele-
vant to patients with advanced-stage disease. Therefore, accu-
rate detection of hepatic involvement at initial presentation is
important in staging. Lugano criteria formally include FDG-
PET/CT as the standard imaging study for staging of FDG-
avid lymphomas. CT scan is preferred in the other non- FDG-
avid or variably FDG-avid lymphomas. A bone marrow biop-
sy has been excluded for the routine staging of HL and most
diffuse large B-cell lymphomas.
In a patient with known nodal disease, secondary liver
involvement on FDG-PET/CT is usually indicated by visual
assessment of diffusely increased or focal uptake, with or
without focal or disseminated nodules. Presence of palpable
liver with abnormal liver chemistries serves as a useful com-
plementary clue. However, PHL is more difficult to character-
ise purely on imaging, and histopathological confirmation is
usually required.
Imaging also plays a crucial role in the assessment of re-
sponse to therapy. Early assessment of response to therapy
allows more individualized therapy that will maximize the
chance of cure while minimizing risk of toxicity. However,
anatomic imaging modalities such as CT, US, and convention-
al MRI sequences may not be sufficiently accurate in
discriminating residual disease from fibrosis or scar tissue.
FDG-PET/CT, on the other hand, provides functional tissue
information, and is superior to conventional imaging modali-
ties in this context. It shows metabolic response earlier than
anatomic response and has been recommended as the standard
of care for response evaluation.
Treatment
Secondary hepatic lymphoma is typically treated with chemo-
therapy, with the treatment regimen dictated by the histologi-
cal subtype. In cases of PHL presenting as a solitary lesion or
limited hepatic disease, surgical resection followed by a com-
bination of chemotherapy and radiotherapy have also been
tried, although no established treatment regimen exists. In
general, PHL has a poor prognosis and the mean survival time
following chemotherapy is 14 months. In contrast, the mean
survival time following surgical treatment is 32 months, and
localized PHL that can be completely resected has a relatively
good prognosis leading some authors to recommend surgery
as the first-line treatment in these cases [2, 50].
Conclusion
There are no pathognomonic imaging features to diagnose
hepatic lymphoma. However, presence of a homogeneous
hypoenhancing intraparenchymal lesion with penetrating ves-
sels or periportal soft-tissue lesion without any significant
mass effect in a middle aged male without any known primary
should alert one to the possibility of primary lymphomatous
involvement of liver, particularly if there is a history of immu-
nosuppression. Secondary involvement of liver by lym-
phoma is relatively easier to diagnose on imaging due
to the concomitant involvement of other organs
Table 3 Revised staging system
for primary nodal lymphomas* Stage Involvement Extranodal (E) status
Limited
Stage I One node or a group of adjacent nodes Single extranodal lesion without
nodal involvement
Stage II Two or more nodal groups on the same
side of the diaphragm





II as above with Bbulky^ disease Not applicable
Advanced
Stage III Nodes on both sides of the diaphragm;
nodes above the diaphragm with spleen
involvement
Not applicable
Stage IV Additional non-contiguous extralymphatic
involvement
Not applicable
*Adapted from reference [38]
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especially spleen and generalized lymphadenopathy, al-
though differentiation with disseminated granulomatous
infection may sometimes be difficult.
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